Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications

References

• AchourAKacemMOne year course of oral sulodexide in the management of diabetic nephropathyJ Nephrol2005185687416299683
   PubMed Web of Science ®Google Scholar
• AdamisAPAltaweelMChanges in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individualsOphthalmology200611323816343627
   PubMed Web of Science ®Google Scholar
• AielloLPVascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disordersN Engl J Med1994331148077526212
   PubMed Web of Science ®Google Scholar
• AielloLPClermontAInhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patientsInvest Ophthalmol Vis Sci200647869216384948
   PubMed Web of Science ®Google Scholar
• AielloLPDavisMDEffect of ruboxistaurin on visual loss in patients with diabetic retinopathyOphthalmology200611322213016989901
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationAll about diabetes [online]2007 Accessed 25 February 2007. URL: http://www.diabetes.org/aboutdiabetes.jsp
   Google Scholar
• AveryRLPearlmanJIntravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathyOphthalmology2006113e11517011951
   PubMed Web of Science ®Google Scholar
• BeisswengerPJHowellSKMetformin reduces systemic methylglyoxal levels in type 2 diabetesDiabetes1999481982029892243
   PubMed Web of Science ®Google Scholar
• BoltonWKCattranDCRandomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyAm J Nephrol200424324014685005
   PubMed Web of Science ®Google Scholar
• BorceaVNourooz-ZadehJAlpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuriaFree Radic Biol Med199926149550010401614
   PubMed Web of Science ®Google Scholar
• BrilVBuchananRAAldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathyDiabetes Care20042723697515451902
   PubMed Web of Science ®Google Scholar
• BrilVBuchananRALong-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathyDiabetes Care200629687216373898
   PubMed Web of Science ®Google Scholar
• BrownMJBirdSJNatural progression of diabetic peripheral neuropathy in the Zenarestat study populationDiabetes Care2004271153915111537
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med200635514324417021319
   PubMed Web of Science ®Google Scholar
• BrownleeMBiochemistry and molecular cell biology of diabetic complicationsNature20014148132011742414
   PubMed Web of Science ®Google Scholar
• BrownleeMThe pathobiology of diabetic complications: a unifying mechanismDiabetes20055416152515919781
   PubMed Web of Science ®Google Scholar
• CampochiaroPAC99-PKC412-003 Study GroupReduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412Invest Ophthalmol Vis Sci2004459223114985312
   PubMed Web of Science ®Google Scholar
• CeramiCFoundsHTobacco smoke is a source of toxic reactive glycation productsProc Natl Acad Sci U S A19979413915209391127
   PubMed Web of Science ®Google Scholar
• CerielloANew insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapyDiabetes Care20032615899612716823
   PubMed Web of Science ®Google Scholar
• ChunDWHeierJSA pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edemaOphthalmology200611317061217011952
   PubMed Web of Science ®Google Scholar
• ClifftJKKasserRJThe effect of monochromatic infrared energy on sensation in patients with diabetic peripheral neuropathy: a double-blind, placebo-controlled studyDiabetes Care200528289690016306551
   PubMed Web of Science ®Google Scholar
• CravenPADavidsonCMIncrease in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipidsDiabetes199039667742347431
   PubMed Web of Science ®Google Scholar
• CravenPAStuderRKNitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cellsDiabetes199746671819075810
   PubMed Web of Science ®Google Scholar
• CsakyKAnti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfallsOphthalmology20031108798112750083
   PubMed Web of Science ®Google Scholar
• CuccurulloCLezziASuppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetesArterioscler Thromb Vasc Biol20062627162317038636
   PubMed Web of Science ®Google Scholar
• CunninghamETJrA phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edemaOphthalmology200511217475716154196
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329977868366922
   PubMed Web of Science ®Google Scholar
• DuXLEdelsteinDHyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylationProc Natl Acad Sci USA20009712222611050244
   PubMed Web of Science ®Google Scholar
• DvorakHFBrownLFVascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesisAm J Pathol19951461029397538264
   PubMed Web of Science ®Google Scholar
• FekeGTBuzneySMRetinal circulatory abnormalities in type 1 diabetesInvest Ophthalmol Vis Sci1994352968758206714
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor: basic science and clinical progressEndocr Rev20042558161115294883
   PubMed Web of Science ®Google Scholar
• FoppianoMLombardoGWorldwide pharmacovigilance systems and tolrestat withdrawalLancet19973493994009033472
   PubMed Web of Science ®Google Scholar
• ForbesJMThallasVThe breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetesFASEB J2003171762412958202
   PubMed Web of Science ®Google Scholar
• ForbesJMThorpeSRModulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathyJ Am Soc Nephrol20051623637215930093
   PubMed Web of Science ®Google Scholar
• FreedmanBIWuerthJPDesign and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II)Control Clin Trials19992049351010503809
   PubMedGoogle Scholar
• FunatsuHYamashitaHVitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edemaOphthalmology200611329430116406543
   PubMed Web of Science ®Google Scholar
• GambaroGKinalskaIOral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trialJ Am Soc Nephrol20021316152512039991
   PubMed Web of Science ®Google Scholar
• GilliesMCSutterFKIntravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trialOphthalmology20061131533816828501
   PubMed Web of Science ®Google Scholar
• GoldbergTCaiWAdvanced glycoxidation end products in commonly consumed foodsJ Am Diet Assoc200410412879115281050
   PubMed Web of Science ®Google Scholar
• GoldinABeckmanJAAdvanced glycation end products: sparking the development of diabetic vascular injuryCirculation200611459760516894049
   PubMed Web of Science ®Google Scholar
• GotoYHottaNEffects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind studyBiomed Pharmacother199549269777579007
   PubMed Web of Science ®Google Scholar
• GragoudasESAdamisAPPegaptanib for neovascular age-related macular degenerationN Engl J Med200435128051615625332
   PubMed Web of Science ®Google Scholar
• GreeneDABrownMBEffect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study GroupNeurology1999535809110449124
   PubMed Web of Science ®Google Scholar
• GuyRJGilbeySGDiabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatmentDiabetologia19884214203290018
   PubMedGoogle Scholar
• HamadaYArakiNRapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathwayBiochem Biophys Res Commun1996228539438920948
   PubMed Web of Science ®Google Scholar
• HamadaYNakamuraJEpalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patientsDiabetes Care20002315394411023149
   PubMed Web of Science ®Google Scholar
• HaritoglouCKookDIntravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edemaRetina200626999100517151486
   PubMed Web of Science ®Google Scholar
• HauptELedermannHBenfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized, controlled pilot study (BEDIP study)Int J Clin Pharmacol Ther20054371715726875
   PubMed Web of Science ®Google Scholar
• HohensteinBHausknechtBLocal VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in manKidney Int20066916546116541023
   PubMed Web of Science ®Google Scholar
• HottaNSakamotoNClinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in JapanJ Diabetes Complications199610168728807467
   PubMed Web of Science ®Google Scholar
• HottaNToyotaTClinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group studyDiabetes Care20012417768211574441
   PubMed Web of Science ®Google Scholar
• HottaNAkanumaYLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications TrialDiabetes Care20062915384416801576
   PubMed Web of Science ®Google Scholar
• HuebschmannAGRegensteinerJGDiabetes and advanced glycoxidation end productsDiabetes Care20062914203216732039
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med200435023354215175435
   PubMed Web of Science ®Google Scholar
• IkedaTIwataKLong-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitusDiabetes Res Clin Pract199943193810369429
   PubMed Web of Science ®Google Scholar
• InoguchiTBattanRPreferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantationProc Natl Acad Sci USA19928911059631438315
   PubMed Web of Science ®Google Scholar
• IsoKTadaHLong-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patientsDiabetes Complications2001152414
   PubMed Web of Science ®Google Scholar
• JaspanJBTowleVLClinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetesMetabolism19863583923083212
   PubMed Web of Science ®Google Scholar
• JorgeRCostaRAIntravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)Retina20062610061317151487
   PubMed Web of Science ®Google Scholar
• KassDAShapiroEPImproved arterial compliance by a novel advanced glycation end-product crosslink breakerCirculation200110414647011571237
   PubMed Web of Science ®Google Scholar
• KatakamiNMatsuhisaMDecreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complicationsDiabetes Care20052827162116249545
   PubMed Web of Science ®Google Scholar
• KinekawaFKuboFEffect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patientsHepatogastroenterology200552471415816460
   PubMedGoogle Scholar
• KoyaDKingGLProtein kinase C activation and the development of diabetic complicationsDiabetes199847859669604860
   PubMed Web of Science ®Google Scholar
• LeeAYChungSSContributions of polyol pathway to oxidative stress in diabetic cataractFASEB J1999123309872926
   PubMedGoogle Scholar
• LeonardDRFarooqiMHRestoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: a double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatmentDiabetes Care2004271687214693984
   PubMed Web of Science ®Google Scholar
• LittleWCZileMRThe effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failureJ Card Fail200511191515812746
   PubMed Web of Science ®Google Scholar
• LiuSLeeIMVitamin E and risk of type 2 diabetes in the women’s health study randomized controlled trialDiabetes20065528566217003353
   PubMed Web of Science ®Google Scholar
• LonnEYusufSHoogwerfBEffects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudyDiabetes Care20022519192712401733
   PubMed Web of Science ®Google Scholar
• MartynCNReidWSix-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve functionDiabetes198736987903111914
   PubMed Web of Science ®Google Scholar
• MasonJO3rdNixonPAIntravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathyAm J Ophthalmol2006142685817011869
   PubMed Web of Science ®Google Scholar
• MellorHParkerPJThe extended protein kinase C superfamilyBiochem J19981281929601053
   PubMedGoogle Scholar
• MorcosMBorceaVEffect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory studyDiabetes Res Clin Pract2001521758311323087
   PubMed Web of Science ®Google Scholar
• MonnierVMSellDRGlycation products as markers and predictors of the progression of diabetic complicationsAnn N Y Acad Sci200510435678116037280
   PubMed Web of Science ®Google Scholar
• NakamuraNYamazakiKEffects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetesIn Vivo2003171778012792982
   PubMed Web of Science ®Google Scholar
• NakayamaMNakamuraJAldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathyDiabetes Care2001241093811375376
   PubMed Web of Science ®Google Scholar
• NishikawaTEdelsteinDNormalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damageNature20004047879010783895
   PubMed Web of Science ®Google Scholar
• OkamotoHNomuraMEffects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesisIntern Med2003426556412924487
   PubMed Web of Science ®Google Scholar
• OshimaYSakaguchiHRegression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathyAm J Ophthalmol2006142155816815267
   PubMed Web of Science ®Google Scholar
• PerssonFRossingPIrbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudyDiabetes2006553550517130503
   PubMed Web of Science ®Google Scholar
• RoglicGUnwinNThe burden of mortality attributable to diabetes: realistic estimates for the year 2000Diabetes Care200592130516123478
   PubMedGoogle Scholar
• RosenfeldPJIntravitreal avastin: the low cost alternative to lucentis?Am J Ophthalmol2006142141316815262
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDRanibizumab for Neovascular Age-Related Macular DegenerationN Engl J Med200635514193117021318
   PubMed Web of Science ®Google Scholar
• ScottJAKingGLOxidative stress and antioxidant treatment in diabetesAnn N Y Acad Sci200410312041315753146
   PubMed Web of Science ®Google Scholar
• SheetzMJKingGLMolecular understanding of hyperglycemia’s adverse effects for diabetic complicationsJAMA200228825798812444865
   PubMed Web of Science ®Google Scholar
• ShenHClaussMCharacterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytesBlood1993812767738490183
   PubMed Web of Science ®Google Scholar
• ShibaTInoguchiTCorrelation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulationAm J Physiol1993265E783938238505
   PubMed Web of Science ®Google Scholar
• SolaSMirMQIrbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) studyCirculation2005111343815655130
   PubMed Web of Science ®Google Scholar
• SoliniAVergnaniLGlycosaminoglycans delay the progression of nephropathy in NIDDMDiabetes Care199720819239135948
   PubMed Web of Science ®Google Scholar
• Sorbinil Retinopathy Trial Research GroupRandomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathyArch Ophthalmol19901081234442119168
   PubMed Web of Science ®Google Scholar
• Sorbinil Retinopathy Trial Research GroupThe sorbinil retinopathy trial: neuropathy resultsNeurology199343114198170559
   PubMed Web of Science ®Google Scholar
• SpaideRFFisherYLIntravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhageRetina200626275816508426
   PubMed Web of Science ®Google Scholar
• SteinbrookRThe price of sight - ranibizumab, bevacizumab, and the treatment of macular degenerationN Engl J Med200635514091217021315
   PubMed Web of Science ®Google Scholar
• StirbanANegreanMBenfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetesDiabetes Care20062920647116936154
   PubMed Web of Science ®Google Scholar
• StrackeHLindemannAA benfotiamine-vitamin B combination in treatment of diabetic polyneuropathyExp Clin Endocrinol Diabetes1996104311168886748
   PubMed Web of Science ®Google Scholar
• StromCSanderBEffect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edemaInvest Ophthalmol Vis Sci2005463855816186374
   PubMed Web of Science ®Google Scholar
• SundkvistGArmstrongFMPeripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat TrialJ Diabetes Complications19926123301611136
   PubMedGoogle Scholar
• SutterFKSimpsonJMIntravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trialOphthalmology20041112044915522370
   PubMed Web of Science ®Google Scholar
• The PKC-DRS Study GroupThe effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trialDiabetes20055421889715983221
   PubMed Web of Science ®Google Scholar
• ThornalleyPJUse of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproductsArch Biochem Biophys2003419314014568006
   PubMed Web of Science ®Google Scholar
• TuttleKRBakrisGLThe effect of ruboxistaurin on nephropathy in type 2 diabetesDiabetes Care20052826869016249540
   PubMed Web of Science ®Google Scholar
• UchidaKKigoshiTNakanoSEffect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitusClin Ther19951746067585850
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet1998352837539742976
   PubMed Web of Science ®Google Scholar
• UribarriJCaiWDiet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjectsAnn N Y Acad Sci20051043461616037267
   PubMed Web of Science ®Google Scholar
• van WijngaardenPCosterDJInhibitors of ocular neovascularization: promises and potential problemsJAMA200529315091315784876
   PubMed Web of Science ®Google Scholar
• VinikAIBrilVTreatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trialClin Ther20052711648016199243
   PubMed Web of Science ®Google Scholar
• VoziyanPAHudsonBGPyridoxamine: the many virtues of a maillard reaction inhibitorAnn N Y Acad Sci200510438071616037308
   PubMed Web of Science ®Google Scholar
• WilliamsMBoltonWDegenhardtTA phase 2 clinical trial of pyridoxamine (pyridorin) in type 2 and type 2 diabetic patients with overt nephropathy (PYR-206) [abstract]J Am Soc Nephro2003147A
   Web of Science ®Google Scholar
• WilliamsMENew potential agents in treating diabetic kidney disease: the fourth actDrugs20066622879817181372
   PubMed Web of Science ®Google Scholar
• WinklerGPalBEffectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathyArzneimittelforschung199949220410219465
   PubMed Web of Science ®Google Scholar
• WoelkHLehrlSBenfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study)Alcohol Alcohol19983363189872352
   PubMed Web of Science ®Google Scholar
• The World Health OrganizationDiabetes Programme: facts and figures [online]2007 Accessed 25 February 2007. URL: http://www.who.int/diabetes/facts/en
   Google Scholar
• ZieglerDNowakHTreatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a meta-analysisDiabetic Med2004211142114984445
   PubMed Web of Science ®Google Scholar
• ZieglerDAmetovAOral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 TrialDiabetes Care20062923657017065669
   PubMed Web of Science ®Google Scholar